TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Metformin and Colesevelam in Human GLP-1 Secretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Normal hemoglobin~* BMI \> 23kg/m2~* HbA1c \<9 %~* Informed concent~Exclusion Criteria:~* Liver disease ( aspartate aminotransferase/alanine aminotransferase \>2 × reference value)~* Chronic intestinal disease~* History of liver and / or gallbladder disease~* Nephropathy (se-creatinine \>110 µM and / or albuminuria)~* Insulin or GLP-1-based antidiabetic treatment~* History of cholecystectomy or surgical resection of bowel segment~* BMI \<23kg/m2 or BMI \>35 kg/m2~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Colesevelam (Type: EXPERIMENTAL): None
- Metformin (Type: EXPERIMENTAL): None
- Placebo (Type: EXPERIMENTAL): None
- Colesevelam + exendin (9-39) (Type: EXPERIMENTAL): None
- Metformin + exendin (9-39) (Type: EXPERIMENTAL): None
- Placebo + + exendin (9-39) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Infusion of Lidocaine, Magnesium and Remifentanil Perioperatively in Patients Undergoing Mastectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients scheduled for elective surgery performed mastectomy;~* Physical Status P1 and P2 of the American Society of Anesthesiology (ASA);~Exclusion Criteria:~* Patients with less than 18 years and above 75 years of age;~* Patients who are allergic to morphine and / or lidocaine and / or remifentanil and / or magnesium sulphate;~* Patients with chronic pain;~* Patients with severe hepatic disease;~* Patients with severe renal disease;~* Patients with neurological disorders;~* Patients included in other clinical currently or within the past three months under general anesthesia studies;~* Patients who refuse to participate in the study;~* Any other condition that in the opinion of the investigator, may pose a risk to the patient or interfere with the study objectives;

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Remifentanil group (Type: ACTIVE_COMPARATOR): Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
- Lidocaine group (Type: ACTIVE_COMPARATOR): Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
- Magnesium group (Type: ACTIVE_COMPARATOR): Patients in lidocaine group received an intravenous bolus injection of 50 mg/kg magnesium sulphate followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
- Magnesium and Lidocaine group (Type: ACTIVE_COMPARATOR): Patients received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of DSM-IV ADHD by K-SADS-PL and confirmed by clinical interview~* Clinical Global Impression-Severity score of at least 4 for ADHD~* Resided with primary caretaker for at least 6 months prior to study entry~Exclusion Criteria:~* History of autism, pervasive developmental disorder, chronic tic disorder, psychosis, or bipolar disorder~* Current major depression or panic disorder~* Systolic or diastolic blood pressure at screening greater than the 95th percentile or less than the 5th percentile for age and body mass index (BMI)~* Any medical condition that might make stimulant or alpha agonist therapy medically inadvisable~* Need for chronic use of other medications with central nervous system effects~* Pregnant, breastfeeding, or beyond menarche and has a positive urine pregnancy test~* History of structural heart defects, syncope, or fainting while exercising~* Clinically significant cardiac abnormality as determined by echocardiogram (ECG) at study entry~* Mental retardation as determined by clinical functional assessment and an IQ estimate of less than 70 based on Wechsler Adult Intelligence Scale (WAIS) subtests

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Group 1: Guan-Guan+Placebo (Type: ACTIVE_COMPARATOR): weeks 1-4: Guanfacine weeks 5-8: Guanfacine + Placebo
- Group 2: Placebo-Placebo+DMPH (Type: ACTIVE_COMPARATOR): weeks 1-4: Placebo weeks 5-8: Placebo+DMPH
- Group 3: Guan-Guan+DMPH (Comb) (Type: EXPERIMENTAL): weeks 1-4: Guanfacine weeks 5-8: Guanfacine+DMPH

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nutritional and Anti-infective Interventions for Malnutrition in Pregnancy (Beleuman Welbodi)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women and consenting to study participation~* Fundal height not greater than 32 cm~* Mid-upper arm circumference ≤23 cm~* Planning to reside in the study area during pregnancy and 6 months post partum~* Attending 1 of the 40 antenatal clinic sites~Exclusion Criteria:~* \< 16 years of age without adult willing to consent~* Known pregnancy complications such as gestational diabetes, pre-eclampsia, hypertension

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ready-to-use supplementary food + anti-infective bundle (Type: EXPERIMENTAL): The women randomized to this arm will receive a ready-to-use-supplementary food (RUSF) designed specifically for pregnancy. The RUSF will provide a total of 520 kcal, 18 g protein, and 200% of recommended daily allowance (RDA) for most micronutrients during pregnancy. The supplement is also optimized to provide excellent protein quality and optimal polyunsaturated fatty acid composition. These women will receive 5 anti-infective interventions: 1) insecticide-treated mosquito net, 2) monthly intermittent preventive treatment of malaria during pregnancy (IPTp) 3) azithromycin at the second and third trimester 4) albendazole given in second trimester, and 5) bacterial vaginosis testing and treatment at enrollment and again at weeks 28-34
- Corn-soy-blend (Type: ACTIVE_COMPARATOR): The women randomized to this arm will receive the standard of care for Sierra Leone. The treatment provided to women in this group includes 3.5 kg super cereal with 350 g vegetable oil every two weeks. This provides 250 mg portion/day of the super cereal and 25g oil/day for the mother. Women will receive the food for the duration of their pregnancy. These women will receive the current recommendations of the government of Sierra Leone, which includes standard intermittent preventive treatment of malaria during pregnancy (IPTp) of 2 doses of sulfadoxine/ pyrimethamine, iron and folic acid supplement with a goal of 90 pills/pregnancy, an insecticide-treated mosquito net, and albendazole for deworming in the second trimester.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women or adult men (\>18 years of age) with various medical diseases requiring long-term prednisolone treatment. Pre-menopausal women should have no plan for pregnancy within 2 years of study entry and agree to practice contraception during this 2-year period.~2. A daily dose of prednisolone (or equivalent) of more than 2.5mg within 3 months of study entry.~3. Having received oral bisphosphonate treatment for at least 2 years.~4. Suboptimal response to bisphosphonate treatment, defined as either one of the following: (1) failure of lumbar spine, femoral neck or total hip BMD values to increase; (2) values of lumbar spine, femoral neck or total hip BMD remain osteoporotic, ie. T scores \< -2.5 or Z scores \< -2.0; or (3) development of new fragility vertebral or non-vertebral fractures despite at least 2 years' treatment with good compliance.~5. Informed consent from patients.~Exclusion Criteria:~1. Patients with previous use of denosumab or teriparatide.~2. Premenopausal women who plan for pregnancy within 2 years of study entry or who do not agree for contraception within this 2-year period.~3. Patients with known bone disorders such as osteomalacia, renal osteodystrophy, and hyperparathyroidism.~4. Patients with unexplained hypocalcemia.~5. Patients with serum creatinine level of \>=200umol/L.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: ACTIVE_COMPARATOR): denosumab
- bisphosphonates (Type: ACTIVE_COMPARATOR): continuation of bisphosphonates

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, 18 years or older;~2. Chronic AD that had been present for at least 3 years before the screening visit;~3. Patients with documented recent history (within 6 months before the screening visit) of inadequate response to out-patient treatment with topical medications, or for whom topical treatments were otherwise inadvisable;~4. Willing and able to comply with all clinic visits and study-related procedures.~Exclusion Criteria:~1. Prior participation in a Dupilumab clinical trial;~2. Treatment with an investigational drug within 8 weeks or within 5 half-lives before the baseline visit;~3. The following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, will likely require such treatment(s) during the first 4 weeks of study treatment:~   * Systemic corticosteroids;~  * Immunosuppressive/immunomodulating drugs;~  * Phototherapy for AD;~4. Treatment with topical corticosteroids, tacrolimus and/or pimecrolimus within 1 week before the baseline visit;~5. Treatment with certain biologics;~6. Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks before the baseline visit;~7. Planned major surgical procedure during the participant's participation in this study;~8. Participant was a member of the investigational team or his/her immediate family;~9. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit~10. Pregnant or breast-feeding women or women planning to become pregnant or breastfeed during the study;~Note: The information listed above is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial therefore not all inclusion/exclusion criteria are listed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo qw (Type: EXPERIMENTAL): Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
- Dupilumab 200 mg qw (Type: EXPERIMENTAL): Two subcutaneous injections of Dupilumab 200 milligram (mg) (for a total of 400 mg) as a loading dose on Day 1, followed by a single 200 mg injection qw from Week 1 to Week 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged \>= 18 to \< 65 years at the time of providing informed consent.~Exclusion Criteria:~* Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, thiomersal, neomycin, polymyxin, or any components of the Study Vaccine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- CSL425 (15 mcg) (Type: EXPERIMENTAL): 15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
- CSL425 (30 mcg) (Type: EXPERIMENTAL): 30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>=18 years of age;~* metastatic colorectal cancer;~* \>=1 target lesion;~* failed first-line chemotherapy with 5-fluorouracil and irinotecan.~Exclusion Criteria:~* previous treatment with oxaliplatin;~* progressive or recurrent disease during or within 6 months of completion of first-line chemotherapy;~* \>=1 previous chemotherapeutic agent or systemic anticancer regimen for metastatic disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- XELOX (Type: EXPERIMENTAL): Participants received XELOX (oxaliplatin and capecitabine). Oxaliplatin was administered 130 mg/m\^2 intravenous (IV) infusion over 2 hours (every 3 weeks \[Day 1\]) before the first dose of capecitabine. Capecitabine was administered orally within 30 minutes after the end of a meal (breakfast and dinner) at a dose of 1000 mg/m\^2 twice-daily (equivalent to a total daily dose of 2000 mg/m\^2), with first dose the evening of Day 1 and last dose the morning of Day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) for up to 8 cycles (24-weeks).
- FOLFOX-4 (Type: ACTIVE_COMPARATOR): Participants received FOLFOX-4 (combination of oxaliplatin, leucovorin \[LV\] and 5-fluorouracil \[5-FU\] combination). Oxaliplatin was administered as an 85 mg/m\^2 IV infusion over 2 hours (on Day 1 only); with LV infusion as 200mg/m\^2 over 2 hours followed by 5-FU, given as 400mg/m\^2 bolus injection over 2-4 minutes, and then as a 600 mg/m\^2 continuous infusion over 22 hours. On Day 2, Leucovorin 200 mg/m\^2 (alone), followed by 5-FU 400 mg/m\^2 bolus injection over 2-4 minutes, and 5-FU 600 mg/m\^2 continuous infusion was repeated over 22 hours. It was (2-week cycles comprising 48 hours of infusion and 12 days of rest) for up to 12 cycles (24- weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged between 18 and 60 years.~* Able to understand the content of informed consent and willing to sign the informed consent~* Able and willing to complete all the secluded study process during the whole 6 months study follow-up period.~* Negative in HIV diagnostic test.~* Negative in serum antibodies (IgG and IgM) screening of COVID-19.~* Axillary temperature ≤37.0°C.~* The BMI index is 18.5-30.0.~* General good health as established by medical history and physical examination.~Exclusion Criteria:~* Family history of seizure, epilepsy, brain or mental disease~* Subject allergic to any component of the investigational vaccine, or a more severe allergic reaction and history of allergies in the past.~* Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months~* Any acute fever disease or infections.~* History of SARS~* Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease.~* Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc.~* Hereditary angioneurotic edema or acquired angioneurotic edema~* Urticaria in last one year~* No spleen or functional spleen.~* Platelet disorder or other bleeding disorder may cause injection contraindication~* Faint at the sight of needles.~* Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months.~* Prior administration of blood products in last 4 months~* Prior administration of other research medicines in last 1 month~* Prior administration of attenuated vaccine in last 1 month~* Prior administration of inactivated vaccine in last 14 days~* Current anti-tuberculosis prophylaxis or therapy~* According to the judgement of investigator,various medical, psychological, social or other conditions, those could affect the subjects to sign informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): 1×10\^11vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
- Arm 2 (Type: ACTIVE_COMPARATOR): 5×10\^10vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
- Arm 3 (Type: PLACEBO_COMPARATOR): Placebo administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, 18 years or older who meet the American College of Rheumatology (ACR) diagnostic criteria for fibromyalgia.~Exclusion Criteria:~* Subjects will be excluded if they have a history of rheumatic disease or other disorders that may compromise reliable representation of subjective symptoms.~* Any other condition that will cause a risk to subjects if they participate in the trial is also a reason for exclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete